CD79B and B-cell chronic lymphocytic leukemia: Only 13% of our patients could afford the cost of IMPT, of which half of them tested for the Matutes CLL score (CD5, CD23, FMC7, surface immunoglobulin, and CD22/CD79b) and the remaining half were tested for CD20 only.